TTX-030 + chemotherpy +/- budigalimab vs chemo alone for 1st line Stage IV pancreatic pts

An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab, compared to chemotherapy alone, for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Disease Types: Pancreatic

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab, compared to chemotherapy alone, for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

For More Information:

https://clinicaltrials.gov/study/NCT06119217?term=An%20open-label%20multicenter%203-arm%20randomized%20Phase%202%20study%20to%20assess%20the%20efficacy%20and%20safety%20of%20TTX-030%20and%20chemotherapy%20with%20or%20without%20budigalimab,%20compared%20to%20chemotherapy%20alone,%20for%20the%20treatment%20of%20patients%20not%20previously%20treated%20for%20metastatic%20pancreatic%20adenocarcinoma%20(TTX-030-003)&rank=1